Compare HOV & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HOV | PHAT |
|---|---|---|
| Founded | 1959 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.5M | 590.6M |
| IPO Year | 1994 | 2019 |
| Metric | HOV | PHAT |
|---|---|---|
| Price | $104.65 | $5.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.05 |
| AVG Volume (30 Days) | 106.9K | ★ 1.7M |
| Earning Date | 12-03-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $2,978,581,000.00 | $175,110,000.00 |
| Revenue This Year | N/A | $79.63 |
| Revenue Next Year | $4.52 | $54.71 |
| P/E Ratio | $64.32 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $90.17 | $5.02 |
| 52 Week High | $148.48 | $18.31 |
| Indicator | HOV | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 49.94 | 34.30 |
| Support Level | $90.85 | $5.02 |
| Resistance Level | $118.46 | $7.72 |
| Average True Range (ATR) | 5.67 | 0.62 |
| MACD | 1.20 | -0.06 |
| Stochastic Oscillator | 91.47 | 28.10 |
Hovnanian Enterprises Inc conducts all of its homebuilding and financial services operations. The company designs, constructs, markets, and sells single-family detached homes, attached townhomes and condominiums, urban infill, and active lifestyle homes in planned residential developments. It has two distinct operations: homebuilding and financial services. Its homebuilding operations are divided geographically into three segments: Northeast, which includes Delaware, Maryland, New Jersey, Ohio, Pennsylvania, Virginia, and West Virginia; Southeast, which includes Florida, Georgia, and South Carolina; and West, which includes Arizona, California, and Texas. The firm generates maximum revenue from the West Segment.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.